Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
The U.S. Food and Drug Administration (FDA) gave Bristol-Myers Squibb’s Opdivo (nivolumab) approval for metastatic small cell lung cancer (SCLC) for patients whose cancer has progressed after platinum-based chemotherapy and at least one other type of therapy.
On a dollar-for-dollar basis, vaccines have probably had a greater positive effect on global health than any other medical advancement, except possibly antibiotics. Yet as a whole, it’s an area that pharma companies tend to not spend a lot of resources on. But there are still many companies that work in this area. Here’s a look at five promising vaccines.
Evotec AG and Haplogen GmbH have been long-term collaboration partners. The companies announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases like chronic obstructive pulmonary disease (COPD).
Western government agencies have been warning of an increase in cyber espionage from nefarious black hats and governments for years. The targets have typically been government and financial installations. But a new warning suggests that biotechnology could be a key target for cyber hackers.
Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
Although no one really knows what President Trump will do to address high drug prices, Pfizer’s chief executive officer Ian Read said he believes it will crack down on drug rebates.
NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.
BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.
JOBS
IN THE PRESS